Safety and Performance Study of the Optimum Transcatheter Aortic Valve

Severe Aortic Stenosis Clinical Trial

Official title:

A First-in-Human Study to Access Feasibility and Safety of the Optimum Aortic Valve Implant

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04076150
• Other study ID #: THUB-CLIN-2018-01
• Status: Recruiting
• Phase: N/A
• Start date: May 18, 2022
• Est. completion date: May 18, 2027

Study information

• Verified date: September 2022
• Source: Thubrikar Aortic Valve, Inc.
• Contact: Mano Thubrikar, PhD
• Phone: 6106308284
• Email: mano.thubrikar[@]tavi.us
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The TAVI (Thubrikar Aortic Valve, Inc.) -1 Study: Safety and Performance Study of the Optimum Transcatheter Aortic Valve- First-in-human study to assess feasibility and safety of the Optimum Aortic Valve Implant

Description:

The purpose of the study is to assess the safety and performance of the Optimum TAV (Transcatheter Aortic Valve) in patients with symptomatic, severe aortic stenosis who are deemed high-risk for SAVR (Surgical Aortic Valve Replacement) or have contraindications or deemed inoperable for SAVR.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5
• Est. completion date: May 18, 2027
• Est. primary completion date: December 18, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

1. Willing and capable to provide informed consent;

2. 70 years of age or older;

3. Echocardiographic or hemodynamic based evidence of calcific (senile) aortic stenosis with one of the following: aortic valve Effective Orifice Area (EAO) = 1.0 cm2 or 0.6 cm2/m2, mean aortic valve gradient =35 mmHg or peak aortic valve velocity > 4 m/sec.

4. Symptomatology due to native aortic stenosis resulting in a New York Heart Association (NYHA) functional classification of II or greater.

5. Aortic valve annular diameter = 21 and = 23mm measured by MSCT (Multi-Slice Computed Tomography).

6. A STS (Society of Thoracic Surgeons) score = 8; or Logistic EuroScore I = 15; or a determination by the local heart team that the co-morbidities not captured by the STS or EuroScore are expected to increase the operative mortality risk to > 15%.

7. Geographically available and willing to comply with follow up.

Exclusion Criteria:

1. Congenital unicuspid or bicuspid aortic valve;

2. Noncalcified aortic valve;

3. Valve eccentricity (calcific or otherwise) that in the opinion of the investigator could compromise procedural success;

4. Severe (Grade 3 to 4) aortic, mitral, or tricuspid valve regurgitation;

5. Moderate to severe mitral stenosis;

6. Myocardial infarction within the past 30 days*

7. Echocardiographic evidence of intracardiac mass, thrombus or vegetation;

8. LVEF (Left Ventricular Ejection Fraction) < 30%;

9. Severe pulmonary hypertension with pulmonary systolic pressure greater than two-thirds of systemic pressure;

10. Hemodynamic instability requiring inotropic drug therapy within the past 14 days or mechanical support within the past 6 months; *

11. Presence of significant aortic disease such as atheroma, thrombus, or aneurysm which, in the opinion of the investigator, precludes safe implant delivery;

12. Blood dyscrasias defined as: acute leukopenia, acute anemia, acute thrombocytopenia, history of bleeding diathesis or coagulopathy;

13. Patient ineligible for or refuses blood transfusions;

14. Unfavorable peripheral vascular anatomy or disease (e.g. severe obstructive calcification, severe tortuosity or small vessels) that would preclude passage of catheters from the femoral arterial access to the aorta as evidenced by peripheral MSCT;

15. Gastrointestinal bleeding within the past 30 days; *

16. Stroke or transient ischemic attack (TIA) within past 3 months;*

17. Renal insufficiency as demonstrated by a serum creatinine > 3.0 mg/dL;

18. End stage renal disease requiring chronic dialysis;

19. Active infection requiring ongoing treatment;

20. Need for emergent surgery or intervention other than the investigational procedure;

21. Hypersensitivity or contraindication to procedural medication(s) and device material(s) (e.g. titanium, nickel, pork) which cannot be adequately pre-medicated;

22. Life expectancy < 1 year due to non-cardiac co-morbid conditions;

23. Currently participating in any other investigational drug or device study;

24. Patient lacking capacity to provide informed consent (history of any cognitive or mental health status that would interfere with study participation)

25. Subject found to have an International Normalized Ratio (INR) greater than 2.0 right before the procedure.

• At the time of procedure, if a subject's medical status has changed since enrollment, the subject shall be re-evaluated for eligibility.

Related Conditions & MeSH terms

• Aortic Valve Stenosis
• Severe Aortic Stenosis

Intervention

Device:
• Transcatheter Aortic Valve (TAV) Implantation With The Optimum TAV System
Treating patients with severe symptomatic aortic stenosis via transcatheter aortic valve implantation by implanting the Optimum TAV inside the native diseased valve via a the Precision Catheter. The Optimum TAV and Precision Catheter together are the Optimum TAV System.

Locations

Country	Name	City	State
Poland	John Paul II Hospital, Dept. of Interventional Cardiology	Kraków

Sponsors (2)

Lead Sponsor	Collaborator
Thubrikar Aortic Valve, Inc.	KCRI

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Device Success	Valve deployed from delivery system successfully	30 days
Primary	Correct Positioning	Deploying a single Optimum TAV in the intended anatomical position and confirming via fluoroscopy as determined by the implanting physician	30 days
Primary	Intended Performance of Optimum TAV - Leaflet Function	Evaluate leaflet function by assessing the effective orifice area (EOA) (units: cm^2) via echocardiography	30 days
Primary	Intended Performance of Optimum TAV - mean aortic valve gradient	Evaluate hemodynamics by assessing the mean aortic valve gradient (units: mmHg) via echocardiography	30 days
Primary	Intended Performance of Optimum TAV - peak aortic valve velocity	Evaluate hemodynamics by assessing the peak aortic valve velocity (units: m/s) via echocardiography	30 days
Primary	Intended Performance of Optimum TAV - Paravalvular Leak	Evaluate proper valve sealing by assessing paravalvular leak via echocardiography and fluoroscopy. If paravalvular leak is determined, it will be classified as mild, moderate, or severe.	30 days